| Objective:To investigate the effects of shumian capsules combine with agomelatine tablets on polysomnography characteristics and serum 5-hydroxytryptamine (5-HT), glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF) in patients with depression and insomnia. Methods:94 patients with depression and insomnia who were admitted to the General Hospital of Eastern Theater of Chinese People ''s Liberation Army from June 2020 to January 2023 were selected. Patients were divided into study group (treated with agomelatine tablets and shumian capsules) and control group (treated with agomelatine tablets) according to the random number table method, 47 cases in each group. The Hamilton Depression Scale-17 (HAMD-17), Pittsburgh Sleep Quality Index (PSQI), Fatigue Scale (FS-14) scale score, 5-HT, BDNF, GDNF, polysomnography (PSG) related indicators [total sleep time (TST), sleep efficiency (SE), non-rapid eye movement sleep 1, 2, 3 (NREM1, NREM2, NREM3)] and adverse reactions were compared between two groups. Results:Compared with control group after treatment, the scores of HAMD-17, PSQI and FS-14 in study group were relatively lower (P<0.05). Compared with control group after treatment, 5-HT, BDNF and GDNF in study group were relatively higher (P<0.05). Compared with control group after treatment, TST, SE, NREM1, NREM2 and NREM3 in study group were relatively higher (P<0.05). There was no difference in the total incidence of adverse reactions between two groups (P>0.05). Conclusion: Patients with depression and insomnia are treat with agomelatine tablets and shumian capsules, the symptoms of insomnia and depression are significantly improve, which may be relate to the improvement of serum 5-HT, BDNF and GDNF levels. |
